fda semaglutide Oral Gets Approval for CV Event Reduction in High-risk Diabetes Patients The FDA's Decision to Ban

Salminen A, Kaarniranta K, Haapasalo A, Hiltunen M, Soininen H, Alafuzoff I

As of mid-2025, Wegovy remains in intermittent shortage, with pharmacies in 23 states reporting backorders

In biochemical and preclinical models, the peptide appears to regulate endothelial activity, cell migration, and cytoskeletal organization through interactions with kinase signaling cascades and nitric oxide related mechanisms

Purpose-built for physicians GLP-1s tied to a particularly noteworthy decrease in likelihood of a dementia diagnosis Key takeaways: Patients prescribed GLP-1s had up to a 44% reduced likelihood of a dementia diagnosis